New Cannabis Data Proves Why This Market Is Still Heading Higher

The pot industry cratered this year, but new data suggests that long-term growth is still intact. Stocks like Cronos Group (TSX:CRON)(NASDAQ:CRON) can help you capitalize.

| More on:
Upwards momentum

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The cannabis market has gone cold — or at least the stocks have. This year, most marijuana ETFs are down more than 50%. Stocks of both big and small companies alike have cratered. Nearly every competitor has been impacted.

This type of contraction is commonplace in emerging markets. According to the Gartner hype cycle, a well-known tool for predicting the rise of high-growth industries, most innovations first experience a boom-bust period before gaining long-term traction.

The dot-com bubble is a perfect example. In the late 1990s, internet stocks were going through the roof only to crater the following year. Despite the severe contraction, however, the digital age was just getting started. Over the next two decades, stocks like Amazon.com, Inc. and Microsoft Corporation accrued trillions in value.

Judging by the fundamentals, the cannabis market is experiencing the same phenomenon. Last year, pot stocks were doubling and tripling in price on a regular basis.

This year, expectations came crashing down to reality. Still, new data suggests that the long-term prospects remain bright. If you want to capitalize on this emerging industry, there’s never been a better time.

New data is encouraging

According to CNN, “Those companies and others that tried to live up to sky-high valuations and overly optimistic projections are being greeted by stark realities: New cannabis markets take time to develop, and ongoing regulatory limbo only fuels uncertainty.” This analysis is spot-on.

After spending decades being banned by nearly every country in the world — indeed, cannabis is still federally illegal in the U.S. — cannabis has slowly been crawling out into the limelight.

If other highly-regulated industries are any indication, the path forward won’t be easy. Both alcohol and tobacco have faced their own shares of scrutiny, punishment, and prohibition over the centuries. Cannabis will be no different.

The road will be bumpy, but long term, the future is bright. Cowen Inc expects global sales to grow by over 30% per year. By 2025, worldwide sales could surpass $70 billion.

Many analysts expect the total market value to eventually hit $200 billion. That’s not surprising considering global tobacco and alcohol sales total a combined $2 trillion.

According to new research compiled by Prohibition Partners, an independent data source for the cannabis industry, legal marijuana could surpass $100 billion over the next five years. That’s several billions higher than estimates from other firms, although it’s important to note that these other firms have also been boosting their projections lately.

Prohibition Partners’ lengthy report contained other surprises, too. The firm believes Europe will eventually surpass North America as the largest source of sales, medical sales will grow faster than recreational sales, and the U.S. will legalize cannabis by 2024. That last point is a big factor in its $100 billion sales projection.

Which stocks will benefit is still uncertain. Companies like Cronos Group have tied themselves at the hip with large partners like Altria Group Inc.

Meanwhile, companies like Hexo Corp are focused on becoming full-fledged cannabis platforms. The future is still unclear, but according to Prohibition Partners, it will be flush with cannabis sales.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool’s board of directors. David Gardner owns shares of Amazon. The Motley Fool owns shares of and recommends Amazon and Microsoft. The Motley Fool recommends HEXO and HEXO and recommends the following options: long January 2021 $85 calls on Microsoft. Fool contributor Ryan Vanzo has no position in any stocks mentioned. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »